Nomination Committee appointed for the Annual General Meeting 2025 in LIDDS

Non Regulatory

GÖTEBORG, SWEDEN – LIDDS AB (publ) today announced the composition of the Nomination Committee for the Annual General Meeting 2024. The Nomination Committee shall, according to decided principles for the appointment of the Nomination Committee, consist of three representatives for the two largest shareholders.

The main task of the Nomination Committee is to submit proposals for Chairman of the Board and other members of the Board, remuneration for Board work, the election and remuneration of auditors. The Nomination Committee shall be composed of members appointed by the two largest shareholders in the company based on ownership of the company as per the end of September 2024.

Accordingly, the following committee members have been appointed:
• Jan Törnell, Chairman
• Niklas Folkesson
• Daniel Lifveredson

The Nomination Committee’s proposals will be presented in the Notice to the AGM 2025 and on the company web site, www.liddspharma.com. Shareholders desiring to submit comments or proposals to the nomination committee can send them via e-mail to info@liddspharma.com.

For additional information, please contact

Mats Wiking, CEO and CFO
Phone: +46 (0)70 620 04 00
E-mail: mats.wiking@liddspharma.com

Daniel Lifveredson, Chairman of the Board
Telefon: +46 (0) 70-916 21 01
Email: d.li@excore.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.

Attachments

Nomination Committee appointed for the Annual General Meeting 2025 in LIDDS